Financial reports
10-Q
2021 Q2
Quarterly report
5 Aug 21
10-Q
2021 Q1
Quarterly report
12 May 21
10-K
2020 FY
Annual report
3 Mar 21
10-Q
2020 Q3
Quarterly report
29 Oct 20
10-Q
2020 Q2
Quarterly report
4 Aug 20
10-Q
2020 Q1
Quarterly report
6 May 20
10-K
2019 FY
Annual report
28 Feb 20
10-Q
2019 Q3
Quarterly report
7 Nov 19
10-Q
2019 Q2
Quarterly report
31 Jul 19
10-Q
2019 Q1
Quarterly report
1 May 19
Current reports
8-K
Completion of Acquisition or Disposition of Assets
5 Oct 21
8-K
Submission of Matters to a Vote of Security Holders
8 Sep 21
8-K
Other Events
30 Aug 21
8-K
Strongbridge Biopharma plc Reports Second Quarter 2021 Financial Results and Provides Corporate Update
5 Aug 21
8-K
Strongbridge Biopharma plc Announces Dates of Special Shareholder Meetings
26 Jul 21
8-K
Other Events
7 Jul 21
8-K
This Announcement Is Being Made Pursuant to Rule 2.5 of the Irish Takeover Rules
24 May 21
8-K
Submission of Matters to a Vote of Security Holders
14 May 21
8-K
Other Events
13 May 21
8-K
Strongbridge Biopharma plc Reports First Quarter 2021 Financial Results and Provides Corporate Update
12 May 21
Registration and prospectus
15-12B
Securities registration termination
15 Oct 21
25-NSE
Exchange delisting
5 Oct 21
S-8 POS
Registration of securities for employees (post-effective amendment)
5 Oct 21
S-8 POS
Registration of securities for employees (post-effective amendment)
5 Oct 21
S-8 POS
Registration of securities for employees (post-effective amendment)
5 Oct 21
S-8 POS
Registration of securities for employees (post-effective amendment)
5 Oct 21
S-8 POS
Registration of securities for employees (post-effective amendment)
5 Oct 21
S-8 POS
Registration of securities for employees (post-effective amendment)
5 Oct 21
POS AM
Prospectus update (post-effective amendment)
5 Oct 21
POS AM
Prospectus update (post-effective amendment)
5 Oct 21
Other
EFFECT
Notice of effectiveness
7 Oct 21
EFFECT
Notice of effectiveness
7 Oct 21
EFFECT
Notice of effectiveness
7 Oct 21
UPLOAD
Letter from SEC
16 Jul 21
CORRESP
Correspondence with SEC
25 Jun 21
UPLOAD
Letter from SEC
21 May 21
EFFECT
Notice of effectiveness
2 Apr 21
CORRESP
Correspondence with SEC
30 Mar 21
UPLOAD
Letter from SEC
30 Mar 21
CT ORDER
Confidential treatment order
29 Aug 18
Ownership
SC 13G/A
ORBIMED ADVISORS LLC
11 Feb 22
SC 13D/A
CAXTON CORP
5 Jan 22
4
Bruce Kovner
5 Jan 22
SC 13D/A
Growth Equity Opportunities Fund III, LLC
25 Oct 21
4
Scott L. Wilhoit
6 Oct 21
4
Richard S Kollender
6 Oct 21
4
Fredric J. Cohen
6 Oct 21
4
JOHN JOHNSON
6 Oct 21
4
Hilde H Steineger
6 Oct 21
4
Marten Steen
6 Oct 21